Astec Lifesciences has informed about Statement of Investor Complaints as per Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th September, 2017.
The above information is a part of company’s filings submitted to BSE.